Background Dual pathway inhibition with 2.5 mg rivaroxaban twice daily plus 100 mg aspirin
once daily may be a promising alternative to 100 mg aspirin antiplatelet therapy for the …

Despite available effective guideline-based preventive therapies, patients with vascular
diseases remain at high-risk of recurrent ischaemic events. Novel therapeutic strategies are …

Background Rivaroxaban is a selective inhibitor of coagulation factor Xa and its combination
with aspirin showed better outcomes in the prevention of recurrent cardiovascular disease …

Background: Low-dose aspirin lowers cardiovascular event risk; dual-pathway inhibition
(DPI) using low-dose aspirin with low-dose rivaroxaban may reduce this risk further. A …

Background: The COMPASS trial (Cardiovascular Outcomes for People using
Anticoagulation Strategies) demonstrated that dual pathway inhibition (DPI) with …

Aims Secondary prevention in patients with coronary artery disease and peripheral artery
disease involves antithrombotic therapy and optimal control of cardiovascular risk factors. In …

Introduction In this review, the role of the rivaroxaban-plus-aspirin approach (dual pathway
inhibition–DPI) in patients with chronic coronary syndrome (CCS) and to perform practical …

Aims To determine the characteristics of patients with coronary artery disease (CAD),
peripheral artery disease (PAD), or both, initiating dual pathway inhibition (DPI) using …

In an attempt to optimise long-term prevention against adverse events in patients with
cardiovascular disease (CVD) several antithrombotic regimens have been tested as …

Peripheral artery disease (PAD) is the third most common manifestation of atherosclerosis
after coronary artery (CAD) and cerebrovascular disease (CVD). People with PAD have …